Sachdev Amit 4

What Happened Amit Sachdev, EVP, Chief Patient & External Affairs Officer at Vertex Pharmaceuticals (VRTX), disposed of a total of 3,364 shares in February 2026 for roughly $1.63 million. On 2026-02-24, 1,518 shares were surrendered/withheld to cover an exercise price or tax liability at $485.11 per share (proceeds/value reported as $736,397). On 2026-02-25, he sold 1,846 shares in an open-market transaction at $486.35 per share for about $897,802. Both actions are reported as disposals (sales/withholding) rather than purchases.

Key Details

• Transaction dates and prices:
  • 2026-02-24: 1,518 shares disposed at $485.11 (code F — payment of exercise price or tax liability) — $736,397.
  • 2026-02-25: 1,846 shares sold open market at $486.35 (code S) — $897,802.
• Combined shares sold/disposed: 3,364; combined proceeds ~ $1,634,199.
• Shares owned after transaction: Not specified in the filing.
• Footnote: Filing notes the transaction(s) were made pursuant to a company-approved Rule 10b5-1 trading plan entered 11/18/2025.
• Filing date: Form 4 filed 2026-02-26 covering the 2026-02-24–02-25 transactions; filing appears to be timely (no late-filing flag in the report).

Context

• The 2026-02-24 disposition (code F) indicates shares were used to satisfy an exercise price or tax withholding obligation — commonly seen when executives exercise options and have shares withheld rather than paying cash.
• The 2026-02-25 open-market sale (code S) is a standard sale of shares; sales can be routine (e.g., for diversification or taxes) and do not by themselves indicate management sentiment about the company.
• The presence of a 10b5-1 plan means at least some trades were pre-planned and executed under an approved trading arrangement, which reduces the likelihood trades were made on non-public material information.